Tumor stroma derived biomarkers in cancer

[1]  Timothy Hunter,et al.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer , 2009, Breast Cancer Research and Treatment.

[2]  Sabine Riethdorf,et al.  Review: Biological relevance of disseminated tumor cells in cancer patients , 2008, International journal of cancer.

[3]  Hai-wei Zhang,et al.  Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells , 2008, Experimental biology and medicine.

[4]  P. Naredi,et al.  Expression pattern and circulating levels of endostatin in patients with pancreas cancer , 2008, International journal of cancer.

[5]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[6]  J. Nesland,et al.  Vascularization in Primary Breast Carcinomas: Its Prognostic Significance and Relationship with Tumor Cell Dissemination , 2008, Clinical Cancer Research.

[7]  J. Folkman,et al.  Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. , 2008, Blood.

[8]  G. Nilsson,et al.  Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. , 2007, Cancer research.

[9]  R. Kalluri,et al.  Type IV collagen α6 chain‐derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth , 2007 .

[10]  Y. Guan,et al.  Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. , 2007, World journal of gastroenterology.

[11]  Kornelia Polyak,et al.  Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.

[12]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[13]  C. Colpaert,et al.  A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation , 2007, Histopathology.

[14]  Na Lu,et al.  Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. , 2007, Biochemical and biophysical research communications.

[15]  T. Salo,et al.  Collagen XVIII modulation is altered during progression of oral dysplasia and carcinoma. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[16]  F. Holstege,et al.  Dissection of a metastatic gene expression signature into distinct components , 2006, Genome Biology.

[17]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[18]  I. Kohane,et al.  Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. , 2006, Journal of proteome research.

[19]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[20]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[21]  Jun Yao,et al.  Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.

[22]  T. Salo,et al.  Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.

[23]  R. Kalluri,et al.  Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Alitalo,et al.  The biology of vascular endothelial growth factors. , 2005, Cardiovascular research.

[25]  B. Uzzan,et al.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. , 2004, Cancer research.

[26]  Raghu Kalluri,et al.  Cancer without disease , 2004, Nature.

[27]  Jian-hua Zhao,et al.  Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. , 2004, Cancer letters.

[28]  N. Ortéga,et al.  Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  H. Joensuu,et al.  Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.

[30]  R. Kalluri.  Basement membranes: structure, assembly and role in tumour angiogenesis , 2003, Nature reviews. Cancer.

[31]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[32]  Raghu Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Zheng Yan,et al.  Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. , 2003, Urology.

[34]  H. Katabuchi,et al.  Serum endostatin levels in patients with epithelial ovarian cancer. , 2003, Anticancer research.

[35]  S. Steinberg,et al.  Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma , 2002, Cancer.

[36]  L. Ellis,et al.  Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[39]  R. Knuechel,et al.  Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? , 2002, Histology and histopathology.

[40]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[41]  T. Nishikawa,et al.  Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer , 2001, Breast Cancer Research and Treatment.

[42]  A. Feldman,et al.  A Prospective Analysis of Plasma Endostatin Levels in Colorectal Cancer Patients With Liver Metastases , 2001, Annals of Surgical Oncology.

[43]  K. Nakayama,et al.  Expression of the Endostatin gene in epithelial ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  A. Feldman,et al.  Serum endostatin levels are elevated in patients with soft tissue sarcoma , 2001, Cancer.

[45]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[46]  H. Ploegh,et al.  Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.

[47]  J. Folkman,et al.  The generation of endostatin is mediated by elastase. , 1999, Cancer research.

[48]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[49]  T. Pihlajaniemi,et al.  The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. , 1998, The American journal of pathology.

[50]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[51]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.

[52]  J. Folkman,et al.  Tumor dormancy due to failure of angiogenesis: role of the microenvironment , 2008, Clinical & Experimental Metastasis.

[53]  R. Kalluri,et al.  Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. , 2008, International Journal of Cancer.

[54]  V. Keshamouni,et al.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. , 2005, The Journal of clinical investigation.

[55]  R. Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Ma-Kang-Zhuo Bai.  Canstatin,a novel matrix-derived inhibitor of angiogenesis and tumor growth , 2003 .

[57]  P. Bioulac-Sage,et al.  Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. , 2001, Cancer research.

[58]  M. Toi,et al.  Circulating Angiogenesis Regulators in Cancer Patients , 2001, The International journal of biological markers.

[59]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.